Neuronetics STIM Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Gross Profit by Business | |||||
| Medical Device | $45.72M-13.6% | $52.93M+2.4% | $51.71M+4.0% | $49.72M— | |
| Operating Income by Business | |||||
| Medical Device | $14.12M— | —— | -$5.13M+85.4% | -$35.11M— | |
| Research And Development Expense by Business | |||||
| Medical Device | $7.66M-39.9% | $12.76M+34.1% | $9.52M+148% | $3.83M— | |
| Revenue by Product | |||||
| Clinic Revenue | $86.98M+1,857% | $4.45M— | —— | —— | |
| Neuro Star Advanced Therapy System | $15.54M-3.5% | $16.09M-5.8% | $17.09M-1.7% | $17.39M+60.0% | |
| Treatment Sessions | $44.41M-13.7% | $51.45M-0.4% | $51.65M+13.7% | $45.43M+7.7% | |
| Concentration Risk % by Product | |||||
| Neuro Star Advanced Therapy System | 143%-7.0pp | 150%— | —— | 193%-37.0pp | |
| Treatment Sessions | 205%— | —— | —— | 259%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Neuronetics break its business down?
- Neuronetics (STIM) reports revenue by business across 2 parts — Clinical Services and Medical Device. Each is extracted from the segment footnotes and tracked over time.
- Where does Neuronetics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Neuronetics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
